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Aldosterone blockade, 
ACE inhibition, and 
proteinuria
Th ere is increasing evidence for the 
role of aldosterone receptor blockade 
in the prevention of fi brosis in the 
heart and kidney. Th e mechanism by 
which aldosterone exerts this eff ect, 
however, remains obscure. In a study 
in this issue, Kramer et al. induced 
nephrotic syndrome in rats by injecting 
adriamycin and tested the eff ect of 
combined angiotensin-converting 
enzyme (ACE) inhibition and 
aldosterone receptor blockade on the 
mechanism of renal injury and fi brosis 
in this model. Th ey found   that the 
combined therapy reduced proteinuria, 
as did ACE inhibition, though 
aldosterone receptor blockade had no 
eff ect. Similarly, there was a reduction 
in the expression of the two marker 
proteins osteopontin and kidney injury 
molecule-1. Th ere was also a reduction 
in renal fi brosis, glomerular sclerosis, 
and expression of mesenchymal 
proteins such as α-smooth muscle 
actin. However, there was no eff ect 
on macrophage infi ltration induced 
in this disease. An interesting clinical 
correlate here was that the treatment 
was started aft er proteinuria became 
established to provide a more relevant 
model for therapy. Although the trend 
for the eff ect of the combined therapy 
was more signifi cant than that for ACE 
inhibition alone, it does not appear, at 
least to this reader, to be a very large 
eff ect. Th e authors initially designed 
their study with another group of 
animals treated with ACE inhibitors 
and amiloride to control for the eff ects 
of volume depletion (since aldosterone 
receptor blockade produces diuresis) or 
hyperkalemia. Unfortunately, it appears 
that the animals did not tolerate this 
regimen well, and hence we are still left  
with the original problem of whether 
blood pressure reduction (or volume 
depletion) was the mechanism for 
protection. An interesting fi nding is 
that aldosterone receptor blockade 
itself was not eff ective. Th is study 
shows the diffi  culty of trying to arrive 
at a decisive experimental protocol to 
answer what appears to be a simple 
question: how does aldosterone 
receptor blockade in humans provide 
an additional eff ect to angiotensin 
blockade? See page 417.
Basolateral carbonic 
anhydrase IV
Carbonic anhydrase facilitates HCO3 
reabsorption in the renal tubule by 
catalyzing the reversible hydration 
of CO2. Th ere are a large number 
of genes with carbonic anhydrase 
activity, and a few are expressed in the 
kidney. Carbonic anhydrase II is the 
cytoplasmic enzyme that mediates this 
function in the proximal tubule and 
intercalated cell. Carbonic anhydrase 
IV (CAIV) is tethered to apical cell 
membranes via a glycosylphosphat
idylinositol (GPI) lipid anchor and 
mediates the reaction in the urinary 
space of proximal and collecting 
tubules. Th ere is good physiological 
evidence for the presence of carbonic 
anhydrase activity in the basolateral 
membrane, and Purkerson et al., as 
they report in this issue, found that 
there is also CAIV staining in the 
basolateral membrane. Th e authors 
transfected cultured inner medullary 
collecting tubule cells with the 
CAIV cDNA and found that it gets 
targeted to both apical and basolateral 
membranes. When basolateral 
vesicles were purifi ed from kidney 
cortex, they were found to contain 
CAIV also. Th e authors also found 
that when these vesicles were treated 
with a phospholipase, they released 
the CAIV, indicating that basolateral 
membrane attachment was also 
mediated by GPI linkage. Previously, 
electrophysiological studies indicated 
that transport of HCO3 across the 
basolateral membrane was inhibited 
by carbonic anhydrase inhibitors, and 
these studies demonstrate that a 
GPI-linked enzyme is likely to 
be associated with the Na:HCO3 
cotransporter kNBC1. See page 407.
Galactosyltransferase 
haplotypes in IgA 
nephropathy
IgA nephropathy is a common 
glomerular disease that has clear 
evidence of genetic predisposition. 
Isolation of IgA from a variety of 
patients had shown that there are 
glycosylation anomalies that might 
favor the trapping of this protein in the 
glomerulus. IgA, like many secreted 
proteins, is glycosylated, and in the 
hinge region of the immunoglobulin 
there is an important O-linked sugar 
group that has N-acetylglucosamine 
attached to the serine or threonine. 
Galactose followed by sialic acid is 
oft en attached to this sugar. Detailed 
studies showed that the IgA of some 
patients had a reduced amount of 
galactosyl residues and/or sialic acid 
residues, thereby exposing the N-
acetylglucosamine residue. Th ese 
studies showed that such IgA molecules 
had a greater propensity for self-
aggregation. Galactosyltransferase 
and its chaperone play important 
roles in glycosylation of IgA and 
provide a possible candidate gene 
for the causation of the abnormal 
galactosylation. To test this hypothesis, 
Li et al., in this issue, studied a 
large number of patients with IgA 
nephropathy with the aim of fi nding an 
association between single-nucleotide 
polymorphisms of galactosyltransferases 
and IgA nephropathy. Five single-
nucleotide polymorphisms were used, 
and they found that the D allele and DD 
genotype were present in a signifi cantly 
lower number of patients with IgA 
nephropathy than in the controls. Th ese 
studies show that this haplotype needs 
to be investigated further to examine 
whether it has a diff erent enzyme activity 
from that of the other haplotypes. 
See page 448.
